Patents Examined by Thea D'Ambrosio
  • Patent number: 11672850
    Abstract: Described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 19 to 50. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 141 to 272. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 273 to 322. Also described herein is an immunogenic composition comprising nucleic acid sequences encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 354 to 458.
    Type: Grant
    Filed: April 26, 2022
    Date of Patent: June 13, 2023
    Assignee: Think Therapeutics, Inc.
    Inventors: David Kenneth Gifford, Brandon Carter
  • Patent number: 11672843
    Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt. % polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: June 13, 2023
    Assignee: CAMURUS AB
    Inventors: Catalin Nistor, Markus Johnsson, Fredrik Tiberg
  • Patent number: 11666638
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: June 6, 2023
    Assignees: Ecole Polytechnique Federale de Lausanne (EPFL), Anokion SA
    Inventors: Jeffrey A. Hubbell, Stephane Kontos, Kristen Marie Lorentz, David Scott Wilson, Shuning Gai
  • Patent number: 11666625
    Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: June 6, 2023
    Assignee: Allegro Pharmaceuticals, LLC
    Inventors: Michael John Mackel, John Park
  • Patent number: 11666634
    Abstract: Described herein are methods of management of functional dyspepsia in a patient by administering an amylin analogue or a CCK composition to the patient. Methods of diagnosing such patient include a standard gastric-emptying assessment using a standardized solid meal along with measurements of blood glucose levels. Another method of diagnosing such patient includes a gastric-emptying scintigraphy assessment with labeled carbohydrates or other assessments to diagnose rapid carbohydrate gastric emptying.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: June 6, 2023
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: William T. Phillips
  • Patent number: 11661456
    Abstract: Pharmaceutical preparations containing polypeptides having particular sialylation patterns, and methods for the treatment of immune-related thrombocytopenia with such preparations, are described.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: May 30, 2023
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Birgit C. Schultes, Chia Lin Chu, Laura Rutitzky, Lynn Zhang, Leona E. Ling
  • Patent number: 11654188
    Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: May 23, 2023
    Assignees: Ecole Polytechnique Federale de Lausanne (EPFL), Anokion, SA
    Inventors: Jeffrey A. Hubbell, David Scott Wilson, Stephane Kontos, Kristen Marie Lorentz, Shuning Gai
  • Patent number: 11633450
    Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: April 25, 2023
    Assignee: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Kevin J. Tracey, Huan Yang, Yousef Al-Abed
  • Patent number: 11603387
    Abstract: The subject invention concerns peptide mimetics of SOCS proteins and methods of use. In one embodiment, a peptide mimetic of the invention binds to a SOCS1 and a SOCS3 target protein. In a specific embodiment, a peptide mimetic of the invention comprises the amino acid sequence of SEQ ID NO:1 and/or SEQ ID NO:2 and/or SEQ ID NO:51, or a functional fragment or variant thereof. In a further embodiment, a peptide of the invention can comprise multiple copies of the mimetic sequence. In one embodiment, a peptide of the invention comprises two or more copies of SEQ ID NO:1 and/or SEQ ID NO:2 and/or SEQ ID NO:51. In a specific embodiment, a peptide mimetic of the invention comprises the amino acid sequence of SEQ ID NO:3 and/or SEQ ID NO:4 to and/or SEQ ID NO:52, or a functional fragment or variant thereof. The subject invention also pertains to methods of treating and/or preventing autoimmune conditions and/or disorders.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: March 14, 2023
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Howard M. Johnson, Joseph Larkin, Chulbul M. Ahmed, Lindsey Jager
  • Patent number: 11578109
    Abstract: This invention relates to a method of selecting a collection of frame-shift peptides (CFSPs) to produce a universal cancer vaccine peptide collection (CVP) for prophylaxis and treatment of patients with hereditary and sporadic micro-satellite instability (MSI) tumors. This invention relates as well to a method of producing a CVP by selecting a subset of frame-shift peptides (FSPs) from the CFSP and optionally modifying the FSP's amino acid (aa) sequence to generate modified FSPs (mFSPs). The invention further relates to nucleic acid collections encoding a CVP of FSPs and/or mFSPs in one or more vaccine vectors that can be used also simultaneously. These CVPs, nucleic acids and vectors are used for the prophylaxis or treatment of MSI cancers.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 14, 2023
    Assignee: NOUSCOM AG
    Inventors: Alfredo Nicosia, Elisa Scarselli, Guido Leoni, Armin Lahm
  • Patent number: 11549937
    Abstract: Compositions, devices and methods are described for improving adhesion, attachment, and/or differentiation of cells in a microfluidic device or chip. In one embodiment, one or more ECM proteins are covalently coupled to the surface of a microchannel of a microfluidic device. The microfluidic devices can be stored or used immediately for culture and/or support of living cells such as mammalian cells, and/or for simulating a function of a tissue, e.g., a liver tissue, muscle tissue, etc. Extended adhesion and viability with sustained function over time is observed.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: January 10, 2023
    Assignee: EMULATE, INC.
    Inventors: Daniel Levner, Kyung Jin Jang, Jacob Fraser, S. Jordan Kerns, Antonio Varone, Dongeun Huh
  • Patent number: 11542302
    Abstract: Compositions and methods for treating a depressive disorder or an anxiety disorder in a subject in need of such treatment are described herein. A therapeutically effective amount of a composition comprising a melanocortin 5 receptor (MC5R) peptide ligand according to the following: in a pharmaceutically acceptable carrier is administered to the subject. Xaa can be Cha or Pro. The MC5R peptide is a selective MC5R antagonist, and administration thereof to the subject can treat the depressive or anxiety disorder with clinical improvement observed in a relatively short time.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: January 3, 2023
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Victor J. Hruby, Minying Cai, Caurnel Morgan
  • Patent number: 11535654
    Abstract: The present invention addresses the problem of providing: a fusion protein or conjugated protein having excellent cell membrane permeability, containing a partial peptide derived from human, and suitable for intracellular delivery; an intracellular delivery carrier comprising such a fusion protein or conjugated protein; a partial peptide; a cell membrane permeation enhancer comprising the partial peptide; DNA; and a vector. The fusion protein or conjugated protein has a partial peptide comprising at least seven consecutive amino acid residues of an amino acid sequence encoded by a predetermined DNA, and a ligand directly or indirectly bound to the partial peptide and having the capability of binding to cell surfaces. The ligand is preferably an antibody. The intracellular delivery carrier comprises the fusion protein or conjugated protein. The cell membrane permeation enhancer comprises the partial peptide.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: December 27, 2022
    Assignee: Keio University
    Inventors: Kei Sudo, Keisuke Niikura, Nobuhide Doi
  • Patent number: 11536714
    Abstract: Compositions, devices and methods are described for improving adhesion, attachment, and/or differentiation of cells in a microfluidic device or chip. In one embodiment, one or more ECM proteins are covalently coupled to the surface of a microchannel of a microfluidic device. The microfluidic devices can be stored or used immediately for culture and/or support of living cells such as mammalian cells, and/or for simulating a function of a tissue, e.g., a liver tissue, muscle tissue, etc. Extended adhesion and viability with sustained function over time is observed.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: December 27, 2022
    Assignee: EMULATE, INC.
    Inventors: Daniel Levner, Kyung Jin Jang, Jacob Fraser, S. Jordan Kerns, Antonio Varone, Dongeun Huh
  • Patent number: 11519903
    Abstract: Compositions, devices and methods are described for improving adhesion, attachment, and/or differentiation of cells in a microfluidic device or chip. In one embodiment, one or more ECM proteins are covalently coupled to the surface of a microchannel of a microfluidic device. The microfluidic devices can be stored or used immediately for culture and/or support of living cells such as mammalian cells, and/or for simulating a function of a tissue, e.g., a liver tissue, muscle tissue, etc. Extended adhesion and viability with sustained function over time is observed.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: December 6, 2022
    Assignee: EMULATE, INC.
    Inventors: Daniel Levner, Kyung Jin Jang, Jacob Fraser, S. Jordan Kerns, Antonio Varone, Dongeun Huh
  • Patent number: 11506653
    Abstract: Compositions, devices and methods are described for improving adhesion, attachment, and/or differentiation of cells in a microfluidic device or chip. In one embodiment, one or more ECM proteins are covalently coupled to the surface of a microchannel of a microfluidic device. The microfluidic devices can be stored or used immediately for culture and/or support of living cells such as mammalian cells, and/or for simulating a function of a tissue, e.g., a liver tissue, muscle tissue, etc. Extended adhesion and viability with sustained function over time is observed.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: November 22, 2022
    Assignee: EMULATE, INC.
    Inventors: Daniel Levner, Kyung Jin Jang, Jacob Fraser, S. Jordan Kerns, Antonio Varone, Dongeun Huh
  • Patent number: 11506652
    Abstract: Compositions, devices and methods are described for improving adhesion, attachment, and/or differentiation of cells in a microfluidic device or chip. In one embodiment, one or more ECM proteins are covalently coupled to the surface of a microchannel of a microfluidic device. The microfluidic devices can be stored or used immediately for culture and/or support of living cells such as mammalian cells, and/or for simulating a function of a tissue, e.g., a liver tissue, muscle tissue, etc. Extended adhesion and viability with sustained function over time is observed.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: November 22, 2022
    Assignee: EMULATE, INC.
    Inventors: Daniel Levner, Kyung JIn Jang, Jacob Fraser, S. Jordan Kerns, Antonio Varone, Dongeun Huh
  • Patent number: 11492416
    Abstract: Methods of inhibiting platelet activation and aggregation using antibodies or peptide vaccines having binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing or treating thrombosis in a subject using such antibodies.
    Type: Grant
    Filed: May 12, 2019
    Date of Patent: November 8, 2022
    Inventor: Kai Yuan Xu
  • Patent number: 11484595
    Abstract: A carrier molecule composition. Specific implementations may include: a carrier molecule including at least one cell penetrating peptide (CPP) where the carrier molecule may include at least one hydrophobic domain and where the carrier is non-covalently associated with a biologically active molecule in one of a micelle and a liposome.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: November 1, 2022
    Assignee: JYSK Skin Solutions PTE. LTD.
    Inventors: Siak-Khim Tan, Janifer Yeo-Tan
  • Patent number: 11466064
    Abstract: Compositions and methods are provided for the treatment or prevention of chemotherapy-induced peripheral neuropathy and hearing loss in a subject in need thereof. The methods involve administering to the subject a bclw protein, a BH4 domain-containing fragment thereof, or a bclw mimetic. Also provided are exemplary bclw mimetics.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: October 11, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Rosalind Segal, Loren D. Walensky, Lisa Vaughn Goodrich, Sarah Elizabeth Raissi, Maria F. Murphy, Gregory H. Bird